NanoZymeX

Spun out of research at the University of Basel, the technology aims to improve therapies for rare genetic conditions such as Pompe disease (a rare genetic disorder that affects how the body breaks down glycogen, leading to progressive muscle damage) by increasing therapeutic activity in affected tissues.

NanoZymeX has raised €164k across 1 funding round from 1 investor, most recently a round in Mar 2026. Based in Basel, Switzerland; active in Healthtech. Data as of 28 Oct 2026.